Sector Alpha Week of 2026-07-29
Sector Alpha — machine-written from the numbers · Data as of 2026-07-29

Smith & Nephew plc

SNN
Healthcare · Medical Devices

Smith & Nephew plc's earnings have outrun its stock. EPS grew +52.3% in a year against a +2.8% price move.

The sharpest disagreement: annual EPS moved +52.3% against a +2.8% price move — the market has not yet caught up with the delivery.

The price is building a base (15 weeks in). Underneath, the last four quarters read improving — profit +65.0% year on year, and 222% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.

Stage
Improving
fundamental trajectory, 12 quarters
Price
$32.6
+2.8% 1Y
P/E
21.5×
of its own 9-year range
Revenue (Dec 25)
$3.2 B
+7.4% YoY
Profit (Dec 25)
$0.3 B
+65.0% YoY
Operating margin
11.2%
+0.1 pp YoY
ROE
12%
FY25
ROIC
8.7%
vs WACC 7.1% → +1.6 pp
Cash conversion
222%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Smith & Nephew plc trades at $32.6, building a base and 15 weeks into that stage. That is −0.6% against its own 200-day average. It sits at 35% of a 52-week range of $30 to $38. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week.

Today the stock is building a base — week 15 of stage 1. At $32.6 it trades −0.6% versus its 200-day average and sits at 35% of its 52-week range ($30–$38).

Jul 26: $32.6 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
−0.6% versus the 200-day line, week 15 of stage 1
Price50-day avg200-day avg
S1S3S1S3S2S1$39.4$34.6$29.9$25.1$20.3$$33$33Jul 23Apr 24Jan 25Oct 25Jul 26
S1S3S1S3S2S1$39.4$34.6$29.9$25.1$20.3$$33$33Jul 23Jan 25Jul 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (526 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 16Jul 26

Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved −5% while the S&P 500 moved +248% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: how the P/E reads against its own history.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

Smith & Nephew plc trades at 21.5× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 21.5× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 21.5× vs a null× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly step line (right axis). 8.6-year window; loss-period spikes above 25× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
against too little history to rank
P/EEPS (TTM) (quarterly)
26.6×$3.921.9×$2.917.2×$1.912.5×$1.07.8×$0.0×$13.73×$2Jan 18Feb 20Apr 22Jun 24Jul 26
26.6×$3.921.9×$2.917.2×$1.912.5×$1.07.8×$0.0×$13.73×$2Jan 18Apr 22Jul 26
P/E
21.5×
too little history to rank
PEG
2.08
derived from 3-year earnings growth

Why the multiple sits where it does: over the past year annual EPS moved +52.3% against a +2.8% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the −4.5%/yr price move, ~+1.9%/yr came from earnings growth and ~−6.4 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

03 · Stage: Improving

Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Smith & Nephew plc reads as improving on its fundamental arc. Improving — profit growth bottomed 3 quarters ago at −49.5% and has held its recovery at +110.2%, ROCE lifting at 17.5%. The read is built from 12 quarters across 4 curves, on full evidence.

Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from
RevenueProfitEPS
12%126%8.3%79%4.3%31%0.3%−16%−3.7%−64%%%11.2%110.2%113.3%Jun 20Dec 22Dec 25
12%126%8.3%79%4.3%31%0.3%−16%−3.7%−64%%%11.2%110.2%113.3%Jun 20Dec 22Dec 25
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
19%15%11%6.6%2.6%%17.5%Jun 20Dec 22Dec 25
19%15%11%6.6%2.6%%17.5%Jun 20Dec 22Dec 25
Revenue growth
Steady high
latest +11.2% · span −2.6% to +11.2%
Profit growth
Flat
latest +110.2% · span −50.5% to +110.2%
EPS growth
Flat
latest +113.3% · span −50.0% to +113.3%
ROCE
Rising
latest 17.5% · span 3.7%–17.5%

Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.

Growth, year by year: revenue +6.0% in FY25, profit +53.7% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
7.0%67%5.1%33%3.3%0.0%1.4%−33%−0.5%−67%%%6%53.7%FY21FY23FY25
7.0%67%5.1%33%3.3%0.0%1.4%−33%−0.5%−67%%%6%53.7%FY21FY23FY25
TTM growth by quarter Trailing-twelve-month growth versus the year-ago TTM, per quarter, %: revenue (left axis); profit and EPS (right axis). The acceleration read compares the last 4 quarters (+11.2%) with the last 8 annualized (+10.7%).
revenue stabilising, profit accelerating
Revenue TTM YoYProfit TTM YoYEPS TTM YoY
12%126%8.3%79%4.3%31%0.3%−16%−3.7%−64%%%11.2%110.2%Jun 20Dec 22Dec 25
12%126%8.3%79%4.3%31%0.3%−16%−3.7%−64%%%11.2%110.2%Jun 20Dec 22Dec 25
Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+6.0%+5.7%
Profit+53.7%+42.0%
EPS+52.3%+41.1%
Stock price+2.8%+2.0%−4.5%−0.2%
Revenue YoY (Dec 25)
+7.4%
latest quarter vs a year ago
Profit YoY (Dec 25)
+65.0%
latest quarter vs a year ago
Revenue 10y
4.3%
long-run compound pace

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

04 · 4-Factor Sector Score

4-Factor Sector Score

45.3/100 — rank 30 of 30 in Medical Devices · 35% evidence confidence · provisional, ranked below fully-evidenced peers

Smith & Nephew plc scores 45.3 out of 100 against the 30 companies it is compared with in Medical Devices, ranking 30. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 17.6 + 12.6 + 10.7 + 4.4 = 45.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Smith & Nephew plc reported $3.2 B of revenue in the Dec 25 quarter, +7.4% year on year. That is the 7th straight quarter of year-on-year growth. Over 4 years it has compounded at 4.3% a year. The last full year, FY25, came in at $6.2 B. The last four reported quarters add to $12.0 B.

Smith & Nephew plc reported $3.2 B of revenue in the Dec 25 quarter, +7.4% year on year. That is the 7th straight quarter of year-on-year growth. Over 4 years it has compounded at 4.3% a year. The last full year, FY25, came in at $6.2 B. The last four reported quarters add to $12.0 B.

FY25 revenue came in at $6.2 B (+6.0% on the year), capping 4 years at 4.3% compound. The latest quarter (Dec 25) printed $3.2 B, +7.4% year on year — the 7th consecutive quarter of year-over-year growth.

FY25 revenue $6.2 B (+6.0% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
4.3% a year over 4 years
RevenueYoY growth
6.77.0%5.05.1%3.33.3%1.71.4%0.0−0.5%$ B%$6B6%FY21FY23FY25
6.77.0%5.05.1%3.33.3%1.71.4%0.0−0.5%$ B%$6B6%FY21FY23FY25
Dec 25: $3.2 B (+7.4% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
7th straight quarter of growth
Revenue (quarterly)YoY growth
3.531%2.618%1.74.9%0.9−8.2%0.0−21%$ B%$3B7.4%Jun 20Dec 22Dec 25
3.531%2.618%1.74.9%0.9−8.2%0.0−21%$ B%$3B7.4%Jun 20Dec 22Dec 25

Pace check: the last four quarters averaged +5.4% growth against the decade's 4.3% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +11.2% over the last 4 quarters against +10.7%/yr over the last 8 — stabilising; TTM profit +110.2% vs +3.0%/yr — accelerating.

→ Revenue grew — did margins hold as it scaled? Next: 11.2% this quarter (+0.1 pp YoY).

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Smith & Nephew plc's operating margin is 11.2% in the Dec 25 quarter, +0.1 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across the last four quarters the operating margin has moved +5.9 percentage points. The current quarter sits inside that band.

Smith & Nephew plc's operating margin is 11.2% in the Dec 25 quarter, +0.1 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across the last four quarters the operating margin has moved +5.9 percentage points. The current quarter sits inside that band.

The latest quarter's operating margin is 11.2%, +0.1 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 7.6%–12.8%, and FY25's 12.8% is the top of that band — a record year.

Why the margin moved: operating margin went +5.9 pp year on year while gross margin went −2.7 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

FY25: 12.8% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
the widest a 7.6–12.8% band over 5 years
operating marginYoY change (pp)
13%4.3%12%2.4%10%0.5%8.7%−1.3%7.2%−3.2%%%12.8%1.4%FY21FY23FY25
13%4.3%12%2.4%10%0.5%8.7%−1.3%7.2%−3.2%%%12.8%1.4%FY21FY23FY25
Dec 25: 11.2% operating margin (+0.1 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
16%18%11%12%7.0%5.5%2.7%−0.8%−1.7%−7.1%%%11.2%0.1%Jun 20Dec 22Dec 25
16%18%11%12%7.0%5.5%2.7%−0.8%−1.7%−7.1%%%11.2%0.1%Jun 20Dec 22Dec 25

→ Margins held — did that reach the bottom line? Next: profit +65.0% in the latest quarter.

07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Smith & Nephew plc earned $0.3 B of net profit in the Dec 25 quarter, +65.0% year on year. It is the 5th consecutive quarter of growth. Full-year FY25 profit was $0.6 B. The 4-year compound rate is 4.9%. That is 10.3% of the quarter's revenue. The same quarter a year earlier earned $0.1 B.

Smith & Nephew plc earned $0.3 B of net profit in the Dec 25 quarter, +65.0% year on year. It is the 5th consecutive quarter of growth. Full-year FY25 profit was $0.6 B. The 4-year compound rate is 4.9%. That is 10.3% of the quarter's revenue. The same quarter a year earlier earned $0.1 B.

Dec 25 profit was $0.3 B, +65.0% year on year — the 5th consecutive quarter of growth. On the full year, FY25 printed $0.6 B (+53.7%), and the 4-year compound rate is 4.9%.

FY25 profit $0.6 B (+53.7% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
4.9% a year over 4 years
Net profitYoY growth
0.767%0.533%0.30.0%0.2−33%0.0−67%$ B%$1B53.7%FY21FY23FY25
0.767%0.533%0.30.0%0.2−33%0.0−67%$ B%$1B53.7%FY21FY23FY25
Dec 25: $0.3 B (+65.0% YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
5th straight quarter of growth
Net profit (quarterly)YoY growth
0.4139%0.379%0.219%0.1−41%0.0−101%$ B%$0B65%Jun 20Dec 22Dec 25
0.4139%0.379%0.219%0.1−41%0.0−101%$ B%$0B65%Jun 20Dec 22Dec 25

Why profit moved: revenue contributed +7.4% and the margin +0.1 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit +62.2% vs revenue +5.4%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.

→ Profit rose — but did the cash follow? Next: 222% of the last 3 years' profit arrived as cash.

08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 222% of Smith & Nephew plc's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $1.3 B of operating cash against $0.6 B of profit. After $0.4 B of capital spending, $0.8 B was left as free cash.

FY25: operating cash of $1.3 B against reported profit of $0.6 B, leaving free cash of $0.8 B after $0.4 B of capital spending. Across the last 3 fiscal years the conversion rate is 222% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $1.3 B vs profit $0.6 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
222% of 3-year profit arrived as cash
Operating cashNet profitFree cash
1.41.00.70.30.0$ B$1B$1B$1BFY21FY23FY25
1.41.00.70.30.0$ B$1B$1B$1BFY21FY23FY25
Dec 25: operating cash $0.9 B = 270% of the quarter's profit Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
1.0582%0.7443%0.5305%0.2166%0.027%$ B%$1B270%Jun 20Dec 22Dec 25
1.0582%0.7443%0.5305%0.2166%0.027%$ B%$1B270%Jun 20Dec 22Dec 25

Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

→ So follow the cash to where it goes. Next: $1.0 B of building over 3 years.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Smith & Nephew plc does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $1.0 B over the last 3 years. Averaged over those years that is 5.4% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $1.0 B over the last 3 fiscal years.

FY25: capex $0.4 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
0.50.30.20.10.0$ B$0BFY21FY23FY25
0.50.30.20.10.0$ B$0BFY21FY23FY25
Dec 25: capex $0.3 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)
0.310.230.160.080.00$ B$0BJun 20Dec 22Dec 25
0.310.230.160.080.00$ B$0BJun 20Dec 22Dec 25

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

→ Does all this activity actually earn its cost of capital? Next: ROE is 12% and the ROIC − WACC spread is +1.6 pp.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Smith & Nephew plc earns a ROE of 12% in FY25. That is up from a trough of 5% in FY23. Return on invested capital clears the cost of that capital by +1.6 percentage points, so growth here adds value rather than only size. The wiring behind it is 10.2% net margin on 0.59× asset turns.

FY25 ROE is 12%, recovered from a FY23 trough of 5% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY25): 10.2% net margin × 0.59× asset turns × 1.98× balance-sheet leverage ≈ 11.9% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 8.7% − 7.1% = a +1.6 pp spread. The 7.1% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.

FY25: ROE 12% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 7.1% cost of capital used on this page.
the climb back from FY23's 5%
ROEROIC (annual)WACC
202%149%96%43%−9.6%%11.9%8%FY21FY23FY25
202%149%96%43%−9.6%%11.9%8%FY21FY23FY25
Dec 25: ROIC 7.4% (TTM) vs WACC 7.1% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
12%11%9.0%7.5%6.0%%7.4%11.6%Apr 23Jun 24Dec 25
12%11%9.0%7.5%6.0%%7.4%11.6%Apr 23Jun 24Dec 25

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.63.

11 · Dividend

Dividend

Smith & Nephew plc pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

Smith & Nephew plc does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

→ No payout to follow. The cash question becomes what the business does with what it earns instead.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Debt-to-equity is 0.63 at the latest reading — modestly levered; a full borrowings history is not in our numbers.

We hold only the latest reading here: a debt-to-equity of 0.63 — a modest level of leverage behind the returns above. A year-by-year borrowings ladder is not in our numbers for this stock, so we say that rather than draw a chart we cannot support.

→ Who owns this, and are they adding or leaving? Next: the register.

13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

No ownership or positioning reading is held for Smith & Nephew plc, so this section names the gap rather than filling it. At typical trading volumes those positions would take about 2.9 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

We hold no ownership or positioning reading for this stock, so this section says that plainly.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Smith & Nephew plc: the Z-score reads 3.42. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 3.42 sits well clear of the distress zone — the balance sheet is not the risk here.

The safety line in one sentence: the Z-score reads 3.42.

Related companies · same industry · Medical Devices Every company is compared on the shape of its own curves, not static ratios. The Revenue, EPS and ROCE columns each draw that company's last 12 quarters as a mini line of the ACTUAL level (trailing-twelve-month revenue and EPS, and the ROCE itself) — so a line that climbs is a business getting bigger, a line that sinks is one shrinking. The colour tracks the same line: green when it is rising or steadily healthy, amber when it is rolling over from a high (still elevated but turning down), red when it is falling, grey when flat or stuck. Colour and direction always agree — a green line never points down. The ROCE curve is the return on capital (annual readings for peers, so a slightly coarser line than the quarterly one at the top of this page). The Stage column then runs the same 12-quarter trajectory classifier used at the top of the page on each company and names where it sits. What lands a company in each bucket: CONSISTENT — growth stays positive across the window and returns are healthy (ROCE ≥ 15%, or ROE ≥ 12% for lenders); IMPROVING — profit or EPS fell into real decline, bottomed a few quarters back, and has climbed back to positive and held there; TURNING AROUND — the same kind of trough but more recent, with the latest quarters just lifting off it (an early, unconfirmed turn); TOPPING OUT — growth is still positive but decelerating hard from its own peak while returns have stopped rising; DETERIORATING — two or more growth curves are shrinking (latest below zero) and staying there, not one soft quarter; MIXED — the curves genuinely disagree, or no clean majority, so no single word fits; NO READ — fewer than eight usable quarters. It is a like-for-like read of every company against its own past, not a ranking against the group.
CompanyP/EMkt capRevenueEPSROCEStage
Smith & Nephew plc this page21.5×$13BImproving
Abbott Laboratories34.7×$187BDeteriorating
Stryker Corporation39.0×$133BTurning around
Medtronic plc22.6×$111BMixed
Boston Scientific Corporation19.3×$68BMixed
Edwards Lifesciences Corporation49.5×$48BDeteriorating
GE HealthCare Technologies Inc.15.4×$29BTopping out
DexCom, Inc.31.4×$29BImproving
Koninklijke Philips N.V.19.6×$25BNo read
STERIS plc29.0×$22BMixed
Zimmer Biomet Holdings, Inc.24.8×$19BDeteriorating
Penumbra, Inc.73.8×$13BMixed
Insulet Corporation39.0×$12BMixed
Globus Medical, Inc.18.8×$11BMixed
Bruker Corporation$10BDeteriorating
Glaukos Corporation$9BNo read
Bio-Rad Laboratories, Inc.53.0×$9BNo read
Bio-Rad Laboratories, Inc.50.0×$8BNo read
LivaNova PLC42.3×$5BNo read
iRhythm Holdings, Inc.$4BNo read
Haemonetics Corporation40.3×$4BMixed
Integer Holdings Corporation25.3×$3BImproving
Establishment Labs Holdings Inc.$3BNo read
TransMedics Group, Inc.17.1×$3BNo read
Axogen, Inc.$2BNo read
Neogen Corporation$2BNo read
UFP Technologies, Inc.29.4×$2BTopping out
NovoCure Limited$2BNo read
Butterfly Network, Inc.$2BNo read
Enovis Corporation$2BNo read
Integra LifeSciences Holdings Corporation$2BDeteriorating
Inspire Medical Systems, Inc.11.6×$1BNo read
AdaptHealth Corp.$1BNo read
Alphatec Holdings, Inc.$1BNo read
CONMED Corporation25.0×$1BDeteriorating
Artivion, Inc.112.1×$1BNo read
Tandem Diabetes Care, Inc.$1BNo read
IRADIMED CORPORATION51.8×$1BMixed
Avanos Medical, Inc.$1BMixed
QuidelOrtho Corporation$1BNo read
12 · Frequently asked questions

Frequently asked questions

What is Smith & Nephew plc's stock price today?

Smith & Nephew plc trades at $32.6, +2.8% over the past year. The company is valued at $13.0 B. The stock sits at 35% of its 52-week range of $30–$38, −0.6% versus its 200-day average. On the tape, the price is building a base, 15 weeks in. — as of 29 July 2026.

What were Smith & Nephew plc's latest quarterly results?

Smith & Nephew plc reported revenue of $3.2 B and net profit of $0.3 B for the Dec 25 quarter. Revenue rose 7.4% and profit rose 65.0% year on year. Earnings per share were $0.77. The operating margin was 11.2%, 0.1 pp higher than a year earlier. — as of 29 July 2026.

What is Smith & Nephew plc's revenue?

Smith & Nephew plc reported revenue of $3.2 B in the Dec 25 quarter, +7.4% year on year. For the full FY25 fiscal year, revenue was $6.2 B (+6.0%). Over the last 4 years revenue compounded at 4.3% a year. — as of 29 July 2026.

What is Smith & Nephew plc's profit?

Smith & Nephew plc earned $0.3 B of net profit in the Dec 25 quarter, +65.0% year on year — the 5th straight quarter of growth. Full-year FY25 profit was $0.6 B. The operating margin ran 11.2% in the latest quarter. — as of 29 July 2026.

What is Smith & Nephew plc's market cap?

Smith & Nephew plc's market capitalisation is $13.0 B at a stock price of $32.6. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 29 July 2026.

Does Smith & Nephew plc pay a dividend?

No — Smith & Nephew plc has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 29 July 2026.

Is Smith & Nephew plc growing?

Yes — Smith & Nephew plc is growing: latest-quarter revenue +7.4% year on year, profit +65.0%, and the margin +0.1 pp at 11.2%. The 4-year compound rates are 4.3% (revenue) and 4.9% (profit). The earnings engine currently reads: improving — as of 29 July 2026.

How is Smith & Nephew plc performing?

Smith & Nephew plc is building a base, 15 weeks in. Its latest quarter's revenue rose 7.4% and profit rose 65.0% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 29 July 2026.

What stage is Smith & Nephew plc in?

Improving — profit growth bottomed 3 quarters ago at −49.5% and has held its recovery at +110.2%, ROCE lifting at 17.5%. The read comes from the last 12 quarters of growth (revenue growth +11.2% latest, profit growth +110.2% latest, eps growth +113.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 29 July 2026.

Is Smith & Nephew plc in an uptrend?

No — the price is building a base (week 15 of stage 1), trading −0.6% versus its 200-day average and at 35% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 29 July 2026.

Is Smith & Nephew plc beating the market?

On recent form, yes — Smith & Nephew plc has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved −5% against the S&P 500's +248% — behind the index over the full window. — as of 29 July 2026.

Will Smith & Nephew plc's stock price go up?

This page publishes no price forecast for Smith & Nephew plc. What it measures instead: the stock price is $32.6, the price is building a base 15 weeks in. Direction is not something this site claims to know. — as of 29 July 2026.

Does Smith & Nephew plc have too much debt?

It is moderate — Smith & Nephew plc's debt-to-equity is 0.63. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 29 July 2026.

What is Smith & Nephew plc's capex?

Smith & Nephew plc spent $1.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.4 B. — as of 29 July 2026.

What is Smith & Nephew plc's cash flow?

Smith & Nephew plc generated $1.3 B of operating cash flow in FY25 and $0.8 B of free cash flow after $0.4 B of capital spending. Reported profit that year was $0.6 B, so operating cash ran ahead of profit. — as of 29 July 2026.

Is Smith & Nephew plc's profit real cash?

Yes — over the last 3 fiscal years, 222% of Smith & Nephew plc's reported profit arrived as operating cash. In FY25, operating cash was $1.3 B against reported profit of $0.6 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 29 July 2026.

How financially safe is Smith & Nephew plc?

On the balance sheet, the Z-score reads 3.42 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 29 July 2026.

Where is Smith & Nephew plc in its business cycle?

Smith & Nephew plc's FY25 operating margin was 12.8%, against a 5-year band of 7.6%–12.8%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 11.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 29 July 2026.

What could break the Smith & Nephew plc story?

The sharpest disagreement: annual EPS moved +52.3% against a +2.8% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 29 July 2026.

Is Smith & Nephew plc a stock worth studying right now?

This is not investment advice. The machine read: Smith & Nephew plc's earnings have outrun its stock. EPS grew +52.3% in a year against a +2.8% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 29 July 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI